WallStSmart
PLYX

Polaryx Therapeutics, Inc. Common Stock

NASDAQ: PLYX · HEALTHCARE · BIOTECHNOLOGY

$3.28
-7.91% today

Updated 2026-06-05

Market cap
$139.57M
P/E ratio
P/S ratio
EPS (TTM)
$-0.14
Dividend yield
52W range
$2 – $49
Volume
0.3M

WallStSmart proprietary scores

16
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
6.0
Quality
B
3.0
Profitability
D
5.0
Valuation
C+
3/9
Piotroski F-Score
Weak
Altman Z-Score
Industry rank
View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target
$10.00
+204.88%
12-Month target
Intrinsic (DCF)
Margin of safety
1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
Insufficient data
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-2.06M

Key financials

Revenue Net Income Free Cash Flow
Metric202320242025TTM
Revenue$0.00$0.00$0.00$0.00
Net income$-3.78M$-30.36M$-8.98M$-2.54M
EPS$-0.14
Free cash flow$-173000.00$-2.57M$-3.94M$-2.06M
Profit margin

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
PLYX$139.57M164.33.05.06.0Avoid
LLY$948.95B7810.010.05.06.0Strong Buy
JNJ$536.54B594.79.03.36.0-71.41%Buy
ABBV$380.57B634.08.04.05.0-55.64%Buy
UNH$343.21B545.35.54.75.5-26.61%Buy
MRK$285.64B503.38.02.75.0-49.34%Hold

Smart narrative

Polaryx Therapeutics, Inc. Common Stock trades at $3.28. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.

Frequently asked questions

What is Polaryx Therapeutics, Inc. Common Stock's stock price?

Polaryx Therapeutics, Inc. Common Stock (PLYX) trades at $3.28.

Is Polaryx Therapeutics, Inc. Common Stock overvalued?

Polaryx Therapeutics, Inc. Common Stock carries a Smart Value Score of 16/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Polaryx Therapeutics, Inc. Common Stock (PLYX)?

The 12-month analyst consensus target is $10.00, about 204.9% above the current $3.28. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio
ROE-260.33%
Beta
50D MA$4.95
200D MA$5.54
Shares out0.05B
Float0.00B
Short ratio
Avg volume0.3M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years